JN210
JN210 is a dual inhibitor of DCN1 and HDAC, with an IC50 of 94.26 nM against human DCN1. JN210 disrupts the UBE2M-DCN1 protein-protein interaction, blocks the neddylation modification of cullin-RING ligases, inhibits HDAC activity and induces histone hyperacetylation. JN210 impairs DNA damage repair function, induces cell apoptosis, exerts cytotoxicity and inhibits tumor growth. JN210 can be used for the research of non-small cell lung cancer.
For research use only. We do not sell to patients.
- Formula: C24H30Cl2N4O3
- Molecular Weight:493.43
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
DCN1 94.26 nM (IC50) |
HDAC1 0.825 μM (IC50) |
HDAC2 2.369 μM (IC50) |
HDAC3 1.280 μM (IC50) |
HDAC6 0.253 μM (IC50) |
HDAC8 0.869 μM (IC50) |
HDAC11 2.894 μM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
1.4 μM
|
Antiproliferative activity against human A549 nonsmall cell lung cancer cells assessed via cell proliferation inhibition assay.
Antiproliferative activity against human A549 nonsmall cell lung cancer cells assessed via cell proliferation inhibition assay.
|
42593931 |
| NCI-H1299 | IC50 |
1.8 μM
|
Antiproliferative activity against human H1299 nonsmall cell lung cancer cells assessed via cell proliferation inhibition assay.
Antiproliferative activity against human H1299 nonsmall cell lung cancer cells assessed via cell proliferation inhibition assay.
|
42593931 |
| HepG2 | IC50 |
2.3 μM
|
Antiproliferative activity against human HepG2 liver cancer cells assessed via cell proliferation inhibition assay.
Antiproliferative activity against human HepG2 liver cancer cells assessed via cell proliferation inhibition assay.
|
42593931 |
In Vitro
JN210 potently inhibits the DCN1-UBE2M protein-protein interaction in a cell-free FP assay with an IC50 of 94.26 nM[1].
JN210 acts as a selective HDAC6 inhibitor in cell-free enzymatic assays, with an IC50 of 0.253 μM, and exhibits moderate activity against most Class I HDACs, negligible activity against Class IIa HDACs, and weak activity against HDAC11[1].
JN210 potently inhibits the proliferation of A549, H1299, and HepG2 cancer cells in vitro, with the highest potency in A549 cells (IC50 = 1.4 μM)[1].
JN210 (0.625-10 μM; 72 h) induces histone H3 and H4 hyperacetylation and upregulates Cullin1 and Cullin3 protein levels in A549 cells[1].
JN210 (1.25-10 μM; 24 h) induces concentration-dependent accumulation of acetylated α-tubulin in A549 cells, confirming HDAC6 target engagement[1].
JN210 (1.25-10 μM; 24 h) induces concentration-dependent upregulation of the p27 tumor suppressor in A549 cells, inhibiting Cullin3-mediated p27 degradation[1].
JN210 (1.25-10 μM; 24 h) induces concentration-dependent DNA double-strand breaks in A549 cells, as measured by elevated γ-H2A.X levels[1].
JN210 (3 μM; 24 h) alters global gene expression in A549 cells, with significant changes in genes related to cytoskeletal organization, cell cycle progression, protein degradation, and the PI3K/Akt signaling pathway[1].
JN210 (5-20 μM; 48 h) induces concentration-dependent G1 phase cell cycle arrest in A549 cells[1].
JN210 (5-10 μM; 48 h) induces concentration-dependent apoptosis in A549 cells, with greater efficacy at 10 μM than the equimolar physical combination of SAHA and NacM-OPT at a total concentration of 20 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A549 nonsmall cell lung cancer cells
-
Concentration:0.625-10 μM
-
Incubation Time:72 h
-
Result:Induced concentration-dependent hyperacetylation of histone H3 and histone H4.
Markedly upregulated Cullin1 and Cullin3 protein levels.
Exerted minimal effect on DCN1 expression.
-
Cell Line:A549 nonsmall cell lung cancer cells
-
Concentration:1.25-10 μM
-
Incubation Time:24 h
-
Result:Induced concentration-dependent accumulation of acetylated α-tubulin.\nInduced concentration-dependent upregulation of p27 protein levels, with a more pronounced effect than the parent DCN1 inhibitor NacM-OPT alone.\nInduced concentration-dependent increases in γ-H2A.X protein levels, a marker of DNA double-strand breaks.
-
Cell Line:A549 nonsmall cell lung cancer cells
-
Concentration:5-20 μM
-
Incubation Time:48 h
-
Result:Induced concentration-dependent G1 phase arrest.
Caused a corresponding decrease in the S-phase cell population.
-
Cell Line:A549 nonsmall cell lung cancer cells
-
Concentration:5-10 μM
-
Incubation Time:48 h
-
Result:Induced concentration-dependent increases in apoptotic cells.
Induced apoptosis in over 60% of A549 cells at 10 μM.
Exerted a greater effect than the equimolar physical combination of SAHA and NacM-OPT (total 20 μM), which induced apoptosis in approximately 30% of cells.
Parmacokinetics
| Species | Dose | Route | T1/2 | Tmax | Cmax | AUC0-t | AUC0-∞ | MRT0-t | MRT0-∞ |
|---|---|---|---|---|---|---|---|---|---|
| Mice[1] | 10 mg/kg | i.p. | 3.45 h | 0.12 h | 4857.2 ng/mL | 1064.7 ng·h/mL | 1285.6 ng·h/mL | 4.5 h | 4.9 h |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice[1]
-
Dosage:10 mg/kg; 30 mg/kg
-
Administration:i.p.; once daily; 15 days
-
Result:Achieved a 44.6% tumor growth inhibition (TGI) rate at 10 mg/kg.
Achieved a 68.6% TGI rate at 30 mg/kg.
Caused no significant body weight loss at both doses.
Showed no obvious tissue damage via histopathological evaluation at both doses.
Chemical Information
-
Molecular Weight 493.43
-
Formula C24H30Cl2N4O3
-
SMILES
O=C(NO)C1=CC=C(CN(C2CCN(CCCC)CC2)C(NC3=CC=C(Cl)C(Cl)=C3)=O)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Immunoprecipitation
Immunoprecipitation (IP) is an experimental method that uses the principle of antibody specific binding to purify and enrich target proteins.
-
Protocol for Bimolecular Fluorescence Complementation (BiFC) Assay
Bimolecular fluorescence complementation detects protein-protein proximity in living or fixed cells by fusing two candidate interaction partners to nonfluorescent N- and C-terminal fragments of a fluorescent protein; when the partners interact or remain close enough, the fluorescent fragments complement, mature, and generate a fluorescent signal at the site of the protein complex. The BiFC readout is fluorescence intensity and subcellular localization of the reconstituted fluorophore, which reflects formation or stabilization of a protein complex rather than direct biochemical binding kinetics; BiFC is therefore useful for mapping where interactions occur in cancer cells, neurons, macrophages, organoid-derived cells, or drug-screening systems, but results should be validated by independent assays such as co-IP or Western blot. BiFC signal formation is delayed by fluorophore maturation and can stabilize otherwise transient complexes, so it is not a real-time reversible interaction assay
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Pull-down
The pull-down assay is an in vitro technique used to detect physical interactions between two or more proteins and an invaluable tool for confirming a predicted protein-protein interaction or identifying novel interacting partners. This method typically involves the use of affinity purification with various wash and elution steps.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Co-Immunoprecipitation
Co-immunoprecipitation technology can verify protein interaction based on the specific immune reaction between antibodies and antigens.
-
Protocol for Yeast Two-Hybrid (Y2H) Assay
The yeast two-hybrid assay detects binary protein-protein interactions by separating a transcription factor into a DNA-binding domain fused to a "bait" protein and a transcriptional activation domain fused to a "prey" protein; if bait and prey interact in yeast, the transcription factor is reconstituted and activates reporter genes such as HIS3, ADE2, lacZ, MEL1, or other selectable/readable reporters. The readout is yeast growth on selective medium and/or reporter activity, which reflects proximity-dependent transcriptional activation in the yeast nucleus rather than direct biochemical binding in the original mammalian, tumor, neuronal, macrophage, or organoid context. Because yeast two-hybrid can generate false positives and false negatives, interaction claims should be validated using independent assays such as co-immunoprecipitation, Western blot, immunofluorescence colocalization, BiFC, pull-down, or mammalian two-hybrid assays.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)